title: Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
abstract: To examine the efficacy of long-term administration of lanthanum carbonate, changes in serum Ca, phosphate, whole parathyroid hormone (wPTH), and ALP were examined in 40 patients who were able to tolerate dosage of lanthanum carbonate over a continuous period of 24 months. Concurrently, concomitant administration of other phosphate binders, cinacalcet, vitamin D, etc., was also examined. After 24 months, serum phosphorus levels (P levels) had decreased to within management target of guidelines, from 6.16 ± 1.44 mg/dL to 5.58 ± 1.15 mg/dL, and this effect was maintained for 2 years. There were no changes in Ca level. wPTH did not change significantly but tended to increase at 12 months. The dose of concomitantly administered calcium carbonate and sevelamer hydrochloride was reduced. The P-lowering function of lanthanum carbonate still held steady at 24 months following the start of dosage. Because of the rising trend seen in wPTH, dose of cinacalcet and/or vitamin D need to be modulated. Reducing the number of concomitantly administered phosphate binder tablets was desirable from the standpoint of patient adherence.
authors.affiliation: Department of Nephrology, Tsukuba Central Hospital, 1589-3 Kashiwada-cho, Ushiku, Ibaraki, Japan. takashi.ishizu@centralweb.sakura.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishizu
authors.forename: Zhang
authors.initials: Z
authors.lastname: Hong
authors.forename: Tsuneaki
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kaneko
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Taru
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods*; D000069603:Sevelamer; D013997:Time Factors
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D000469:Alkaline Phosphatase; D002119:Calcium Carbonate; D002118:Calcium